Research programme: recombinant coagulation factors - CSL Behring

Drug Profile

Research programme: recombinant coagulation factors - CSL Behring

Alternative Names: CSL 626; CSL 650; CSL626 rD'D3-FP; rvWF-FP

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor VIIa stimulants; Von Willebrand factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 28 Feb 2017 CSL 626 rD'D3-FP is in preclinical development for haemophilia (CSL group pipeline, February 2017)
  • 03 Apr 2012 rvWF-FP is still in preclinical development for haemophilia in the US
  • 08 Dec 2011 CSL initiates research programme for rvWF-FP in Haemophilia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top